Index -
P/E -
EPS (ttm) -28.25
Insider Own 1.75%
Shs Outstand 0.85M
Perf Week 27.93%
Market Cap 6.58M
Forward P/E -
EPS next Y -17.25
Insider Trans 201.68%
Shs Float 0.84M
Perf Month 34.55%
Income -12.32M
PEG -
EPS next Q -3.75
Inst Own 2.09%
Short Float 4.11%
Perf Quarter -4.20%
Sales 0.25M
P/S 26.32
EPS this Y 46.67%
Inst Trans -
Short Ratio 0.03
Perf Half Y -6.18%
Book/sh 18.30
P/B 0.42
EPS next Y -19.79%
ROA -82.62%
Short Interest 0.03M
Perf Year -68.15%
Cash/sh 14.62
P/C 0.53
EPS next 5Y -
ROE -103.53%
52W Range 3.82 - 36.60
Perf YTD -12.54%
Dividend Est. -
P/FCF -
EPS past 5Y 75.28%
ROI -108.01%
52W High -78.85%
Beta 1.27
Dividend TTM -
Quick Ratio 5.11
Sales past 5Y -38.82%
Gross Margin 78.40%
52W Low 102.62%
ATR (14) 1.14
Dividend Ex-Date -
Current Ratio 5.11
EPS Y/Y TTM 92.22%
Oper. Margin -5138.00%
RSI (14) 65.14
Volatility 18.56% 22.99%
Employees 9
Debt/Eq 0.03
Sales Y/Y TTM -
Profit Margin -4926.40%
Recom 1.00
Target Price 22.50
Option/Short No / Yes
LT Debt/Eq 0.01
EPS Q/Q 76.46%
Payout -
Rel Volume 0.14
Prev Close 7.29
Sales Surprise -
EPS Surprise 30.65%
Sales Q/Q -
Earnings Mar 27 BMO
Avg Volume 1.13M
Price 7.74
SMA20 38.10%
SMA50 34.90%
SMA200 -20.77%
Trades
Volume 161,784
Change 6.17%
May-02-24 08:30AM
May-01-24 08:30AM
Apr-23-24 08:30AM
Apr-16-24 11:22AM
08:30AM
09:15AM
Loading…
Apr-11-24 09:15AM
Apr-10-24 08:15AM
Apr-03-24 05:30PM
Mar-27-24 08:00AM
Mar-26-24 11:52PM
Feb-15-24 08:35AM
Feb-13-24 08:35AM
Feb-08-24 02:40PM
08:05AM
Jan-30-24 09:25AM
02:01PM
Loading…
Jan-29-24 02:01PM
08:05AM
Jan-09-24 08:00AM
Dec-29-23 04:52AM
(Pharmaceutical Business Review) -9.77%
Dec-28-23 08:00AM
Nov-10-23 08:05AM
Oct-18-23 10:00AM
Oct-11-23 09:05AM
Sep-14-23 07:13PM
Sep-11-23 04:01PM
08:35AM
Sep-07-23 08:30AM
Sep-06-23 08:45AM
Aug-11-23 08:05AM
Aug-09-23 08:05AM
08:45AM
Loading…
Jul-05-23 08:45AM
Jun-22-23 08:30AM
Jun-14-23 08:45AM
Jun-01-23 08:45AM
May-24-23 08:45AM
May-17-23 08:30AM
May-12-23 08:05AM
May-11-23 09:05AM
Apr-06-23 09:00AM
Apr-05-23 08:35AM
Apr-04-23 08:30AM
Apr-03-23 08:30AM
Mar-23-23 08:05AM
Mar-15-23 08:30AM
Mar-01-23 09:05AM
Feb-08-23 08:35AM
Jan-11-23 01:00PM
Jan-10-23 08:35AM
Jan-09-23 08:45AM
Jan-04-23 05:15PM
Dec-30-22 08:45AM
Dec-16-22 08:05AM
Dec-07-22 08:35AM
Dec-01-22 02:44PM
Nov-22-22 08:35AM
Nov-18-22 08:05AM
Nov-17-22 08:30AM
Nov-15-22 11:15AM
Nov-14-22 08:45AM
Oct-11-22 09:25AM
Sep-29-22 08:35AM
Sep-23-22 04:30PM
Sep-21-22 09:23AM
Sep-15-22 08:30AM
Sep-13-22 09:05AM
Aug-17-22 08:35AM
Aug-16-22 04:05PM
Aug-15-22 09:00AM
Aug-12-22 08:30AM
Aug-01-22 08:05AM
Jul-27-22 08:05AM
Jun-29-22 08:30AM
Jun-07-22 08:30AM
May-13-22 09:00AM
May-10-22 05:00PM
May-06-22 08:30AM
May-05-22 08:30AM
May-02-22 08:35AM
Apr-29-22 08:05AM
Mar-30-22 03:47PM
Mar-24-22 08:30AM
Mar-22-22 08:30AM
Mar-18-22 08:30AM
Mar-16-22 08:00AM
Mar-14-22 09:15AM
Mar-09-22 08:30AM
Feb-18-22 08:30AM
Feb-15-22 08:30AM
Feb-08-22 08:00AM
Dec-29-21 08:30AM
Dec-08-21 08:00AM
Nov-30-21 08:00AM
Nov-23-21 08:00AM
Nov-15-21 07:00AM
Oct-22-21 08:00AM
Sep-09-21 08:30AM
Aug-24-21 08:15AM
Aug-20-21 09:25AM
Jul-29-21 08:15AM
Jul-13-21 08:00AM
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Finley John David CEO, CFO, Director Mar 11 '24 Option Exercise 0.00 5,558 0 96,849 Mar 12 06:29 PM Neal James R Director Feb 09 '24 Option Exercise 0.00 10,920 0 10,920 Feb 13 03:08 PM Trenschel Robert J. Director Feb 08 '24 Option Exercise 0.00 10,920 0 10,920 Feb 13 03:08 PM Csimma Cristina Director Feb 08 '24 Option Exercise 0.00 12,800 0 12,862 Feb 13 03:08 PM Diaz Stephanie Director Feb 08 '24 Option Exercise 0.00 12,800 0 12,800 Feb 13 03:08 PM Finley John David CEO, CFO, Director Feb 06 '24 Option Exercise 0.00 6,642 0 91,291 Feb 08 04:37 PM Jones Mitchell Lawrence Chief Medical Officer Feb 06 '24 Option Exercise 0.00 6,891 0 9,815 Feb 08 04:38 PM Finley John David CEO, CFO, Director Feb 06 '24 Buy 0.47 10,000 4,692 84,649 Feb 07 08:30 AM Williams Donald Allen Director Jan 31 '24 Buy 0.60 10,000 6,050 30,000 Feb 01 08:30 AM Finley John David CEO, CFO, Director Jan 31 '24 Buy 0.56 10,000 5,590 74,649 Feb 01 08:30 AM Finley John David CEO, CFO, Director Jan 03 '24 Option Exercise 0.00 1,309 0 64,649 Jan 05 04:00 PM Finley John David CEO, CFO, Director Dec 11 '23 Option Exercise 0.00 5,559 0 63,340 Dec 19 05:57 PM Finley John David CEO, CFO, Director Nov 06 '23 Option Exercise 0.00 3,475 0 47,781 Nov 08 05:01 PM Jones Mitchell Lawrence Chief Medical Officer Nov 06 '23 Option Exercise 0.00 4,556 0 4,556 Nov 08 05:01 PM Finley John David CEO, CFO, Director Oct 03 '23 Option Exercise 0.00 1,309 0 44,703 Oct 05 05:46 PM Williams Donald Allen Director Sep 27 '23 Buy 0.54 20,000 10,800 20,000 Sep 29 09:25 AM Finley John David CEO, CFO, Director Sep 27 '23 Buy 0.54 15,000 8,088 43,394 Sep 29 09:21 AM Trenschel Robert J. Director Sep 14 '23 Sale 0.64 300 192 0 Sep 15 05:15 PM Finley John David CEO, CFO, Director Sep 13 '23 Buy 0.66 15,000 9,825 28,394 Sep 14 05:00 PM Finley John David CEO, CFO, Director Sep 11 '23 Option Exercise 0.00 5,558 0 15,186 Sep 13 04:55 PM Finley John David CEO, CFO, Director Aug 06 '23 Option Exercise 0.00 3,475 0 11,057 Aug 14 06:33 PM Finley John David CEO, CFO, Director Jul 03 '23 Option Exercise 0.00 1,309 0 7,582 Jul 06 06:27 PM Finley John David CEO, CFO, Director Jun 12 '23 Option Exercise 0.00 3,475 0 7,323 Jun 14 06:23 PM
Index -
P/E -
EPS (ttm) -8.88
Insider Own 19.97%
Shs Outstand 2.86M
Perf Week 0.93%
Market Cap 6.21M
Forward P/E -
EPS next Y -1.89
Insider Trans 12.40%
Shs Float 2.29M
Perf Month -6.47%
Income -11.12M
PEG -
EPS next Q -1.18
Inst Own 1.94%
Short Float 8.28%
Perf Quarter -10.70%
Sales 0.00M
P/S -
EPS this Y 55.79%
Inst Trans 4.99%
Short Ratio 0.13
Perf Half Y -69.44%
Book/sh 3.88
P/B 0.56
EPS next Y 50.52%
ROA -154.40%
Short Interest 0.19M
Perf Year -83.56%
Cash/sh 1.65
P/C 1.32
EPS next 5Y 15.00%
ROE -178.52%
52W Range 1.40 - 18.00
Perf YTD -67.57%
Dividend Est. -
P/FCF -
EPS past 5Y 9.70%
ROI -219.96%
52W High -87.94%
Beta 0.58
Dividend TTM -
Quick Ratio 7.71
Sales past 5Y 0.00%
Gross Margin -
52W Low 55.00%
ATR (14) 0.29
Dividend Ex-Date -
Current Ratio 7.71
EPS Y/Y TTM 74.04%
Oper. Margin 0.00%
RSI (14) 51.96
Volatility 9.97% 16.69%
Employees 13
Debt/Eq 0.03
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 44.00
Option/Short No / Yes
LT Debt/Eq 0.01
EPS Q/Q 88.48%
Payout -
Rel Volume 0.06
Prev Close 2.26
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings -
Avg Volume 1.50M
Price 2.17
SMA20 8.77%
SMA50 -0.32%
SMA200 -63.00%
Trades
Volume 88,941
Change -3.98%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-25-24 Initiated
H.C. Wainwright
Buy
$8
Apr-30-24 08:00AM
Apr-11-24 08:00AM
Mar-28-24 08:15AM
Mar-25-24 08:15AM
Feb-21-24 08:15AM
01:00PM
Loading…
Feb-14-24 01:00PM
Feb-06-24 08:30AM
Feb-01-24 04:22PM
Jan-26-24 09:04AM
Jan-25-24 02:40PM
08:30AM
Jan-19-24 07:45AM
Jan-18-24 07:45AM
Jan-02-24 05:06PM
Dec-19-23 09:00AM
09:00AM
Loading…
Dec-13-23 09:00AM
Nov-30-23 08:15AM
Nov-29-23 08:15AM
Nov-13-23 01:40PM
Nov-09-23 08:15AM
Nov-01-23 08:15AM
Oct-13-23 01:08PM
Sep-06-23 08:15AM
Aug-17-23 08:05AM
Aug-15-23 10:20AM
Aug-10-23 04:15PM
Aug-08-23 08:15AM
Jun-14-23 04:15PM
Jun-13-23 08:30AM
May-22-23 08:05AM
08:00AM
Loading…
May-18-23 08:00AM
Apr-28-23 08:15AM
Mar-30-23 04:01PM
Mar-23-23 08:30AM
Mar-17-23 08:30AM
Mar-07-23 08:30AM
Feb-21-23 08:30AM
Feb-15-23 08:30AM
Feb-10-23 08:00AM
Jan-04-23 08:30AM
Dec-14-22 08:30AM
Nov-08-22 04:00PM
08:30AM
Nov-02-22 08:30AM
Nov-01-22 08:30AM
Sep-15-22 08:30AM
Sep-07-22 08:30AM
Aug-16-22 08:30AM
Aug-12-22 09:30AM
Aug-05-22 03:00PM
Aug-04-22 09:30AM
Aug-03-22 04:00PM
Jul-12-22 08:30AM
Jun-24-22 09:06AM
May-12-22 04:20PM
May-05-22 08:30AM
Apr-20-22 08:30AM
Apr-05-22 08:30AM
Mar-30-22 04:00PM
Mar-23-22 08:30AM
Mar-10-22 08:30AM
Jan-26-22 08:15AM
Jan-17-22 08:42AM
Nov-11-21 04:05PM
Nov-04-21 08:15AM
Oct-26-21 08:30AM
Oct-19-21 10:22AM
Oct-12-21 08:30AM
Sep-16-21 11:05AM
08:30AM
Aug-23-21 04:00PM
Aug-20-21 10:54AM
Aug-12-21 05:15PM
Aug-06-21 08:30AM
Aug-05-21 09:51AM
Aug-04-21 08:30AM
Jul-27-21 08:30AM
Jul-08-21 11:20AM
Jul-06-21 08:15AM
Jun-23-21 09:35AM
Jun-17-21 09:15AM
Jun-08-21 09:15AM
Jun-07-21 04:05PM
May-26-21 09:15AM
May-20-21 04:05PM
04:15AM
May-18-21 04:05PM
May-13-21 04:55PM
May-07-21 08:30AM
Mar-25-21 04:06PM
Mar-22-21 09:15AM
Mar-17-21 09:15AM
Mar-02-21 09:15AM
Feb-22-21 08:30AM
Feb-19-21 05:16AM
Feb-17-21 08:00AM
Jan-11-21 10:50AM
Nov-16-20 12:48PM
Nov-12-20 05:02PM
Nov-05-20 09:15AM
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Young David Pres. Research & Development Feb 07 '24 Buy 2.45 21,000 51,526 79,387 Feb 08 04:30 PM Young David Pres. Research & Development Feb 06 '24 Buy 2.53 20,000 50,504 58,387 Feb 07 04:22 PM Lin Patrick Chief Business - Strategy Off Feb 01 '24 Buy 2.40 1,500 3,600 27,478 Feb 01 06:32 PM Lin Patrick Chief Business - Strategy Off Jan 31 '24 Buy 2.37 2,500 5,925 25,978 Feb 01 06:32 PM Ng George K Chief Executive Officer Jan 30 '24 Buy 2.70 10,000 27,000 20,000 Jan 31 04:37 PM Yorke Justin W Director Jan 30 '24 Buy 2.69 8,000 21,544 31,232 Jan 31 04:34 PM Young David President & CEO Jun 12 '23 Buy 0.80 40,000 32,000 470,424 Jun 12 04:31 PM
Index RUT
P/E -
EPS (ttm) -4.04
Insider Own 0.40%
Shs Outstand 11.63M
Perf Week -2.48%
Market Cap 288.19M
Forward P/E -
EPS next Y -1.45
Insider Trans 0.00%
Shs Float 11.58M
Perf Month -3.95%
Income -46.30M
PEG -
EPS next Q -0.71
Inst Own 65.05%
Short Float 2.43%
Perf Quarter 22.67%
Sales 4.76M
P/S 60.54
EPS this Y 47.85%
Inst Trans 0.91%
Short Ratio 15.57
Perf Half Y 29.53%
Book/sh 7.71
P/B 3.21
EPS next Y 31.33%
ROA -21.79%
Short Interest 0.28M
Perf Year 34.31%
Cash/sh 13.21
P/C 1.88
EPS next 5Y 19.00%
ROE -38.39%
52W Range 13.48 - 27.00
Perf YTD 33.95%
Dividend Est. -
P/FCF -
EPS past 5Y -20.43%
ROI -22.31%
52W High -8.22%
Beta 0.86
Dividend TTM -
Quick Ratio 8.68
Sales past 5Y 46.25%
Gross Margin 79.05%
52W Low 83.83%
ATR (14) 1.09
Dividend Ex-Date -
Current Ratio 8.68
EPS Y/Y TTM -104.25%
Oper. Margin -460.03%
RSI (14) 46.73
Volatility 3.59% 4.06%
Employees 13
Debt/Eq 1.40
Sales Y/Y TTM -21.06%
Profit Margin -973.16%
Recom 1.67
Target Price 57.00
Option/Short Yes / Yes
LT Debt/Eq 1.34
EPS Q/Q -191.80%
Payout -
Rel Volume 0.45
Prev Close 25.44
Sales Surprise -50.07%
EPS Surprise -419.44%
Sales Q/Q 23.35%
Earnings Mar 08 BMO
Avg Volume 18.10K
Price 24.78
SMA20 -2.53%
SMA50 -1.24%
SMA200 29.72%
Trades
Volume 8,213
Change -2.59%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-29-24 Initiated
Leerink Partners
Outperform
$40
Sep-07-21 Downgrade
Wedbush
Outperform → Neutral
$22
Jun-29-21 Initiated
Aegis Capital
Buy
$60
Jan-19-21 Reiterated
H.C. Wainwright
Buy
$30 → $56
Jan-18-18 Reiterated
H.C. Wainwright
Buy
$38 → $49
Oct-17-17 Resumed
H.C. Wainwright
Buy
$38
Sep-05-17 Upgrade
Wedbush
Neutral → Outperform
$9 → $19
Jun-12-17 Initiated
H.C. Wainwright
Buy
$15
Nov-14-16 Downgrade
Wedbush
Outperform → Neutral
$17 → $14
Mar-11-16 Reiterated
Wedbush
Outperform
$6 → $3
Jul-23-15 Downgrade
Jefferies
Buy → Hold
Jul-22-15 Downgrade
Piper Jaffray
Overweight → Neutral
Jul-22-15 Downgrade
Ladenburg Thalmann
Buy → Neutral
Oct-10-14 Resumed
ROTH Capital
Buy
$9
Apr-29-14 Upgrade
MLV & Co
Hold → Buy
$7
Mar-11-14 Downgrade
MLV & Co
Buy → Hold
$8 → $7
Mar-05-14 Reiterated
Ladenburg Thalmann
Buy
$6.50 → $10
Oct-31-13 Reiterated
MLV & Co
Buy
$7.50 → $8
May-09-13 Reiterated
Ladenburg Thalmann
Buy
$5 → $6
May-14-12 Initiated
Cowen & Co
Outperform
Show Previous Ratings
Apr-30-24 07:30AM
Apr-25-24 07:30AM
Apr-24-24 09:00AM
Apr-03-24 09:00AM
Mar-21-24 07:30AM
04:05PM
Loading…
Mar-19-24 04:05PM
Mar-08-24 12:53PM
08:12AM
07:52AM
(Associated Press Finance)
07:30AM
Feb-28-24 07:30AM
Feb-16-24 08:00AM
Jan-18-24 08:30AM
Jan-11-24 04:05PM
Jan-08-24 07:30AM
07:30AM
Loading…
Jan-02-24 07:30AM
Dec-20-23 07:30AM
Dec-19-23 07:30AM
Nov-07-23 07:50AM
(Associated Press Finance) -6.44%
07:30AM
Oct-31-23 07:30AM
Sep-25-23 07:30AM
Sep-06-23 07:30AM
Aug-31-23 10:43PM
Aug-13-23 10:07AM
Aug-08-23 08:21AM
(Associated Press Finance)
07:30AM
Jun-23-23 06:14PM
Jun-22-23 07:30AM
Jun-20-23 07:30AM
09:29AM
Loading…
May-16-23 09:29AM
May-09-23 07:53AM
07:30AM
Apr-26-23 07:30AM
Mar-30-23 07:30AM
Mar-21-23 07:30AM
Mar-10-23 05:36AM
Mar-09-23 07:50AM
07:30AM
Mar-06-23 08:28AM
Feb-28-23 07:30AM
Jan-06-23 07:00PM
Jan-04-23 07:30AM
Dec-22-22 07:30AM
Dec-07-22 07:44AM
Nov-22-22 07:01AM
Nov-06-22 09:24AM
Nov-03-22 09:05AM
07:30AM
Sep-27-22 08:30AM
Sep-21-22 07:30AM
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
07:30AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
07:30AM
May-03-22 08:15AM
Apr-20-22 08:24AM
Mar-21-22 07:30AM
Mar-15-22 06:21AM
Mar-10-22 09:43AM
07:30AM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Jan-21-22 10:21AM
Dec-23-21 07:30AM
Dec-21-21 07:30AM
Dec-16-21 07:30AM
Nov-22-21 11:46AM
Nov-15-21 06:01AM
Nov-04-21 10:15AM
07:40AM
07:30AM
Oct-28-21 03:06PM
Oct-27-21 04:50AM
Oct-14-21 06:57AM
Oct-08-21 03:35AM
Sep-22-21 07:30AM
Sep-21-21 12:33PM
Sep-20-21 07:30AM
Sep-13-21 07:30AM
Sep-07-21 01:49PM
Aug-10-21 04:35PM
Aug-05-21 08:45AM
07:30AM
Jul-29-21 03:05PM
Jul-28-21 07:30AM
Jul-15-21 06:38AM
04:17AM
04:00AM
Jun-23-21 03:16PM
XOMA Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sitko Bradley Chief Investment Officer Oct 03 '23 Buy 13.89 250 3,472 5,600 Oct 04 04:30 PM Sitko Bradley Chief Investment Officer Oct 02 '23 Buy 14.25 1,500 21,375 5,350 Oct 04 04:30 PM Hughes Owen Exec Chairman and Interim CEO Oct 02 '23 Buy 13.83 1,000 13,830 3,500 Oct 04 04:30 PM Hughes Owen Exec Chairman and Interim CEO Sep 26 '23 Buy 14.43 2,499 36,061 2,500 Sep 27 04:30 PM Hughes Owen Exec Chairman and Interim CEO Sep 25 '23 Buy 14.65 1 15 1 Sep 27 04:30 PM Sitko Bradley Chief Investment Officer May 31 '23 Buy 17.13 1,500 25,700 3,500 Jun 02 04:30 PM Hughes Owen Interim CEO May 24 '23 Buy 23.79 1,032 24,551 2,000 May 25 04:30 PM Hughes Owen Interim CEO May 23 '23 Buy 23.46 968 22,706 968 May 25 04:30 PM Sitko Bradley Chief Investment Officer May 23 '23 Buy 19.00 850 16,150 3,850 May 25 04:30 PM Sitko Bradley Chief Investment Officer May 19 '23 Buy 19.50 1,000 19,500 3,000 May 22 04:30 PM Sitko Bradley Chief Investment Officer May 16 '23 Buy 23.20 500 11,602 2,000 May 17 05:20 PM Sitko Bradley Chief Investment Officer May 15 '23 Buy 23.40 1,500 35,100 1,500 May 16 04:13 PM Sitko Bradley Chief Investment Officer May 12 '23 Buy 18.99 2,000 37,985 2,000 May 16 04:13 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite